Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $65.00 | Buy | Deutsche Bank |
| 12/13/2024 | $74.00 → $35.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2024 | $72.00 → $38.00 | Outperform → Neutral | Mizuho |
| 10/24/2024 | $24.00 | Sell | UBS |
| 10/7/2024 | Buy → Neutral | Guggenheim | |
| 4/29/2024 | $74.00 | Outperform | Leerink Partners |
| 11/20/2023 | $60.00 | Overweight | JP Morgan |
| 11/2/2023 | Overweight | Cantor Fitzgerald |
Deutsche Bank initiated coverage of Immunocore with a rating of Buy and set a new price target of $65.00
Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously
Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously
4 - Immunocore Holdings plc (0001671927) (Issuer)
4 - Immunocore Holdings plc (0001671927) (Issuer)
4 - Immunocore Holdings plc (0001671927) (Issuer)
SCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)
8-K - Immunocore Holdings plc (0001671927) (Filer)
10-Q - Immunocore Holdings plc (0001671927) (Filer)
KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025 Conference call today, August 7 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, August 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and de
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss their financial results and provide a business and portfolio update. Audio
RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by Immunocore (NASDAQ:IMCR) as the distribution and commercialization partner for KIMMTRAK, for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in Turkey and across the Middle East, North Africa, Caucasus and the Commonwealth of Independent States (CIS) regions. Immunocore is a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically i
4 - Immunocore Holdings plc (0001671927) (Issuer)
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s
KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025 Conference call today, August 7 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, August 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and de
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss their financial results and provide a business and portfolio update. Audio
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)
SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)